Truist initiated coverage of DexCom (DXCM) with a Buy rating and $102 price target The firm sees DexCom driving higher adoption into the large and underpenetrated multi-billion dollar type 1 and type 2 diabetes addressable markets as a “leading innovator” in the rapidly growing Continuous Glucose Monitoring space, the analyst tells investors. Mid-2024 execution stumbles should be in the “rearview” and the firm sees DexCom sustaining mid-teens-plus revenue growth, the analyst added.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Dexcom’s Strategic Growth and Market Expansion Justifies Buy Rating
- Here’s Why Goldman Sachs Is Bullish on DexCom Stock (DXCM)
- DexCom initiated with a Buy at Goldman Sachs
- DexCom price target raised to $102 from $82 at Citi
- Dexcom’s Strategic Advancements and Market Opportunities Justify Buy Rating with $105 Price Objective